Safety of ocrelizumab in multiple sclerosis: Long-term adverse event analyses based on initial exposure quartilesS. L. Hauser,A. Bar-Or,M. S. Weber,H. Kletzl,H. M. Schneble,Q. Wang,L. KapposMULTIPLE SCLEROSIS JOURNAL（2022）引用 0|浏览14AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
